Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
The Impact of Comorbidities on Sarcoidosis
share announcement

The Impact of Comorbidities on Sarcoidosis

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular Genetics and Genetic Diseases".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 4870

Special Issue Editor

Dr. Claudio Tana

E-Mail Website
Guest Editor
COVID-19 Medicine Unit and Geriatrics Clinic, S.S. Annunziata Hospital of Chieti, 66100 Chieti, Italy
Interests: internal medicine; rare disorders; pain; headache; sarcoidosis; comorbidity
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Sarcoidosis is an uncommon disorder characterized by the presence of noncaseating and non-necrotizing granulomas involving all organs almost ubiquitously, although some, such as the lungs, are more affected.

Clinical manifestations are often dominated by lung impairment, but the picture varies depending on the site mainly involved, and nonspecific symptoms can dominate. Some disorders often mimic sarcoidosis; the histopathological features and pathophysiology can overlap and the impact of comorbidities is largely unknown.

A comorbidity can be defined as a medical condition which occurs simultaneously with (correlated or not) another and could influence the patient’s outcome. The molecular mechanisms and pathophysiology of this interaction are the current object of study.

The aim of this Special Issue is to report on the most recent advances regarding the impact of comorbidities on sarcoidosis. Both translational research articles and reviews are welcomed, as well as commentaries concerning recent research evidence.

Dr. Claudio Tana
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • sarcoidosis
  • comorbidity
  • genetics
  • molecular mechanisms
  • translational research
  • disease
  • pathophysiology
  • lungs
  • cardiovascular risk

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

15 pages, 1302 KiB  
Review
Sarcoidosis Associated Pulmonary Hypertension
by Alexander Liu, Laura C. Price, Rakesh Sharma, Athol U. Wells and Vasileios Kouranos
Biomedicines 2024, 12(1), 177; https://doi.org/10.3390/biomedicines12010177 - 13 Jan 2024
Cited by 1 | Viewed by 1548
Abstract
In patients with sarcoidosis, the development of pulmonary hypertension is associated with significant morbidity and mortality. The global prevalence of sarcoidosis-associated pulmonary hypertension (SAPH) reportedly ranges between 2.9% and 20% of sarcoidosis patients. Multiple factors may contribute to the development of SAPH, including [...] Read more.
In patients with sarcoidosis, the development of pulmonary hypertension is associated with significant morbidity and mortality. The global prevalence of sarcoidosis-associated pulmonary hypertension (SAPH) reportedly ranges between 2.9% and 20% of sarcoidosis patients. Multiple factors may contribute to the development of SAPH, including advanced parenchymal lung disease, severe systolic and/or diastolic left ventricular dysfunction, veno-occlusive or thromboembolic disease, as well as extrinsic factors such as pulmonary vascular compression from enlarged lymph nodes, anemia, and liver disease. Early diagnosis of SAPH is important but rarely achieved primarily due to insufficiently accurate screening strategies, which rely entirely on non-invasive tests and clinical assessment. The definitive diagnosis of SAPH requires right heart catheterization (RHC), with transthoracic echocardiography as the recommended gatekeeper to RHC according to current guidelines. A 6-min walk test (6MWT) had the greatest prognostic value in SAPH patients based on recent registry outcomes, while advanced lung disease determined using a reduced DLCO (<35% predicted) was associated with reduced transplant-free survival in pre-capillary SAPH. Clinical management involves the identification and treatment of the underlying mechanism. Pulmonary vasodilators are useful in several scenarios, especially when a pulmonary vascular phenotype predominates. End-stage SAPH may warrant consideration for lung transplantation, which remains a high-risk option. Multi-centered randomized controlled trials are required to develop existing therapies further and improve the prognosis of SAPH patients. Full article
(This article belongs to the Special Issue The Impact of Comorbidities on Sarcoidosis)
►▼ Show Figures

Figure 1

16 pages, 1408 KiB  
Review
Sarcoidosis and COVID-19: At the Cross-Road between Immunopathology and Clinical Manifestation
by Claudio Tana, Francesco Cinetto, Cesare Mantini, Nicol Bernardinello, Marco Tana, Fabrizio Ricci, Andrea Ticinesi, Tiziana Meschi, Riccardo Scarpa, Francesco Cipollone, Maria Adele Giamberardino and Paolo Spagnolo
Biomedicines 2022, 10(10), 2525; https://doi.org/10.3390/biomedicines10102525 - 09 Oct 2022
Cited by 10 | Viewed by 2825
Abstract
Coronavirus disease 2019 (COVID-19) has been associated with dysregulation of the immune system featuring inappropriate immune responses, exacerbation of inflammatory responses, and multiple organ dysfunction syndrome in patients with severe disease. Sarcoidosis, also known as Besnier–Boeck–Schaumann disease, is an idiopathic granulomatous multisystem disease [...] Read more.
Coronavirus disease 2019 (COVID-19) has been associated with dysregulation of the immune system featuring inappropriate immune responses, exacerbation of inflammatory responses, and multiple organ dysfunction syndrome in patients with severe disease. Sarcoidosis, also known as Besnier–Boeck–Schaumann disease, is an idiopathic granulomatous multisystem disease characterized by dense epithelioid non-necrotizing lesions with varying degrees of lymphocytic inflammation. These two diseases have similar clinical manifestations and may influence each other at multiple levels, eventually affecting their clinical courses and prognosis. Notably, sarcoidosis patients are at high risk of severe COVID-19 pneumonia because of the underlying lung disease and chronic immunosuppressive treatment. In this narrative review, we will discuss interactions between sarcoidosis and COVID-19 in terms of clinical manifestations, treatment, and pathogenesis, including the role of the dysregulated renin–angiotensin system, altered immune responses involving increased cytokine levels and immune system hyperactivation, and cellular death pathways. Full article
(This article belongs to the Special Issue The Impact of Comorbidities on Sarcoidosis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop